Navigation Links
Daclizumab shows potential for new immunoregulatory approach to treating MS
Date:2/16/2010

bo, and is currently enrolling patients. The Phase 3 DECIDE trial is expected to be initiated in the second quarter of 2010.

About CHOICE

The CHOICE study is the first randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of daclizumab (DAC) when added to IFNβ therapy. The study enrolled 230 patients, ages 18 to 55 years, with active relapsing MS who had an entry score of five or less on the Expanded Disability Status Scale (EDSS). The patients had to be taking a stable IFNβ regimen for a minimum of six months prior to enrollment. During the year prior to enrollment, patients had to have experienced at least one MS relapse or incurred at least one MS lesion of the brain or spinal cord while on a stable IFNβ regimen.

Patients remained on their baseline IFNβ regimens and were randomized in a ratio of 1:1:1 to three "add-on" treatment groups for 24 weeks: 2mg/kg daclizumab administered subcutaneously every two weeks (DAC high dose/ IFNβ); 1mg/kg daclizumab administered every four weeks (DAC low dose/ IFNβ); or placebo (placebo/ IFNβ).

The primary endpoint of the study was the total number of new or enlarged Gd-CELs measured monthly on brain MRI scans collected between weeks eight to 24. Additional endpoints included changes in the number and volume of lesions on TI- and T2-weighted MRIs, clinical relapse as assessed by the annualized relapse rate (ARR) and time to relapse, changes in EDSS and Multiple Sclerosis Functional Composite-3 (MSFC-3) scores, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), clinical laboratory abnormalities and adverse events (AEs).

Compared with patients on placebo/IFNβ therapy alone, there was a 72 percent reduction in the number of new or enlarged Gd-CELs between weeks eight and 24 in the DAC high dose/IFNβ group (p=0.004, 95% CI 34%, 88%) and a 25 percent reduction in the DAC low dose/IFN&
'/>"/>

Contact: Kate Weiss
617-914-6524
GCI Health
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
2. Mescal worm test shows DNA leaks into preservative liquids
3. Boost for Prostate Cancer Screening - Report Shows Mortality Reduction as High as 31%
4. Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy
5. UCBs Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis
6. Tiny test tube experiment shows reaction of melting materials at the nano scale
7. New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations
8. Topical erectile dysfunction therapy shows promise
9. Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost
10. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
11. Video shows nanotube spins as it grows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015   University of ... announced today the signing of an exclusive option ... Maryland, Baltimore (UMB) to develop diagnostics to detect inflammatory ... Crohn,s disease (CD). Drs. Florian Fricke and ... both were with the University of Maryland School of ...
(Date:5/6/2015)... May 06, 2015 Park Systems ... NX-Hivac, the only high vacuum AFM system in the ... failure analysis semiconductor manufacturing. Park NX-Hivac is ideal for ... analysis solutions in highly doped semiconductor processing where more ... , The high vacuum scanning spreading resistance microscopy (SSRM) ...
(Date:5/6/2015)... Dr Jaspreet Singh , Senior Research ... a speech at the 2015 Asian Starch Conference, to be ... Center.  , ... topic: ,Potato Starch: A Potential Source for the Creation ... Co-editor of a 528 page text book entitled "Advances ...
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines ... of its initial public offering of 9,367,708 shares ... of $18.00 per share, including shares of common ... underwriters of their option to purchase additional shares. ... to Blueprint Medicines were approximately $168.6 million, before underwriting ...
Breaking Biology Technology:Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 2Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 3Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 2Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2Blueprint Medicines Announces Closing of Initial Public Offering 2
... Pa., March 31 Genaera,Corporation (Nasdaq: GENR ) today ... 31, 2007. The net loss for the year ended,December 31, ... as compared to a net loss of $21.2 million, or ... 31, 2006. The net loss for,the quarter ended December 31, ...
... for the 12 Months Ended December 31, 2007, ... today results for the financial year ended December,31, 2007., ... million) compared to,DKK 136 million (approximately USD 27 million) ... million (approximately USD 86 million).,This compares to an Operating ...
... Immunosyn,Corporation (OTC Bulletin Board: IMYN), a biotechnology firm ... rights to,the biopharmaceutical SF-1019, has announced its results ... For the year ended December 31, 2007, the ... $26,000 in interest expense which,was funded from advances ...
Cached Biology Technology:Genaera Corporation Announces 2007 Financial Results 2Genaera Corporation Announces 2007 Financial Results 3Genaera Corporation Announces 2007 Financial Results 4Genaera Corporation Announces 2007 Financial Results 5Genaera Corporation Announces 2007 Financial Results 6Genmab Announces Year End 2007 Financial Results 2Genmab Announces Year End 2007 Financial Results 3Genmab Announces Year End 2007 Financial Results 4Genmab Announces Year End 2007 Financial Results 5Immunosyn Corporation Announces 2007 Results, Files 10KSB 2Immunosyn Corporation Announces 2007 Results, Files 10KSB 3
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... New Orleans, LA Jay K. Kolls, MD, Professor ... Orleans School of Medicine, has been awarded $1.8 million over ... of the National Institutes of Health to study whether antibodies ... the fungus that causes Pneumocystis carinii pneumonia (PCP) ...
... eat with water, nutrients and anchorage. Understanding how roots grow ... crop yields, which will be necessary to address food security ... of scientists, led by the Centre for Plant Integrative Biology ... a plant hormone is crucial in controlling the growth of ...
... Medical mycologists in The South Texas Center for Emerging ... The University of Texas at San Antonio (UTSA) have ... a respiratory infection of humans, commonly called Valley Fever, ... For the first time, the researchers have genetically ...
Cached Biology News:Hormone clue to root growth 2UTSA infectious disease researchers advancing vaccine against Valley fever 2
...
... Apoptosis is an evolutionarily conserved form ... cellular process. The central component of ... enzymes called caspases. These enzymes participate ... triggered in response to pro-apoptotic signals and ...
... System provides optimized reagents and protocols for ... genes by insertion of group II introns. ... group II introns and utilizes a simple ... II intron for specific insertion into the ...
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Biology Products: